FDMT News and Press, 4D Molecular Therapeutics Inc. From 10/13/25

Cystic Fibrosis Foundation to provide up to $11 million in additional funding to accelerate development of 4D-710 for cystic fibrosis, following program and clinical data review by its independent scientific advisors Funding supports second 4D-710 dosing ≥1 year post initial Phase ...

2025-09-30 05:08:14 ET 4D Molecular Therapeutics (FDMT) seems an attractive buy in late 2025, especially for long-term investors with a high-risk appetite and who can tolerate short-term volatility. With shares priced at $8.35 (as of September 29) and a market capitalization of around $...

2025-09-09 18:13:24 ET 4D Molecular Therapeutics, Inc. (FDMT) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:50 PM EDT... Read the full article on Seeking Alpha For further details see: 4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan St...

Julie Clark, M.D., promoted to Chief Medical Officer Liansheng Zhu, Ph.D., joined as SVP, Biometrics and Data Quality 4FRONT-1 Phase 3 trial enrollment continues to exceed expectations, with enrollment completion now expected in Q1 2026 Addition of distinguished retina ind...

EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefi...

4D Molecular Therapeutics Inc. (FDMT) is expected to report $-0.88 for Q2 2025

2025-08-11 08:07:26 ET More on 4D Molecular Therapeutics 4D Molecular to layoff about 25% of workforce Seeking Alpha’s Quant Rating on 4D Molecular Therapeutics Historical earnings data for 4D Molecular Therapeutics Financial information for 4D Molecul...

4D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedule Presented positive 60-week results from 4D-150 SPECTRA clinical trial in DME Streamlined organization to driv...

EMERYVILLE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefi...

A look at the top 10 most actives in the United States Erayak Power Solution Group Inc. (RAYA) rose 41.4% to $0.084 on volume of 564,200,836 shares LOBO EV TECHNOLOGIES LTD. (LOBO) rose 118.7% to $0.7864 on volume of 419,806,285 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose...